|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
Datamonitor, July 2010, Pages: 245
Introduction
Datamonitor forecasts the inflammatory bowel disease market to become increasingly competitive with the anticipated launch of seven new products, spanning five drug classes from 2010 to 2019. These therapies are forecast to inject over $1 billion into a market projected to reach up to $5.7 billion by 2019 and offer more therapy choice to specific patient groups.
Scope
-Segmentation and analysis of products across all stages of the IBD pipeline with in-depth discussion of key Phase II and III pipeline therapies
-Insight and analysis of market potential including robust epidemiology forecasts, and a review of key opinion leader requirements for new products
-Ten-year indication-specific forecasts of seven pipeline products, with a comparison of their relative clinical and commercial attractiveness
-Review of unmet needs based on key opinion leader interviews and a focus on innovative early-stage drug development and assessment of future treatment
Highlights
Datamonitor identified 108 products across all stages of development, but these treatments vary immensely by target. The diversity of the pipeline will broaden future therapy choice for specific patient groups, such as TNF-failure patients and the mild to moderate group.
Opinion leaders cite the re-randomization of patients responding to initial treatment in Crohn's disease trials as an effective design. In ulcerative colitis assessing induction and maintenance treatment in separate studies of new drugs will play a significant role in drug labeling, particularly for the European Medicines Agency.
Two key late-stage pipeline drugs show particular clinical and commercial potential. Simponi (golimumab) is viewed positively by opinion leaders for ulcerative colitis. In Crohn's disease, chemokine antagonist GSK1605786 (Traficet-EN) is anticipated to reach the market by 2017 and could potentially threaten biologics as a maintenance agent.
Reasons to Purchase
-Understand the recent advances in the inflammatory bowel disease pipeline and gain insight into leading gastroenterologist opinion
-Access sales forecasts for late-stage pipeline products and understand new product positioning through analysis of clinical and commercial factors
-Evaluate the unmet needs in both Crohn's disease and ulcerative colitis and the challenges faced in clinical trial development
Customers who bought this item also bought
Therapeutic Clinical Intelligence - Inflammatory Bowel Disease
Anti-TNF Therapies in IBD: Opinion Leader Insight into Current & Future Treatment Practices
Thought Leader Insight & Analysis Report - Crohn’s Disease, Ulcerative Colitis Q1 2010
Ulcerative Colitis: KOL Insights on Treatment Practices and Unmet Needs
Thought Leader Insight & Analysis Report - Inflammatory Bowel Disease Q2 2011
Crohn’s Disease: Future Treatment Scenarios and Opportunities
Crohn's Disease: KOL Insights on Treatment Practices and Unmet Needs
Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, 2nd Edition
Inflammatory Bowel Disease Therapeutics - Global Strategic Business Report
|
|
|
|
